secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2025-09-30T23:59:59+00:00
Accession:  0001193125-25-224053
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene appoints Dr. Hussein Sweiti as CMO; former J&J bladder cancer lead
-------------------------------------------------------------------------

- Dr. Sweiti appointed Chief Medical Officer effective September 29, 2025.
- Previously Global Medical Head, Oncology at J&J; led bladder cancer portfolio and recent FDA NMIBC approval.
- Will oversee global clinical development for detalimogene; BLA submission planned for 2H 2026.
- Brings 15+ years experience in surgical oncology, drug development, and regulatory submissions.
- Appointed after target enrollment reached in pivotal detalimogene NMIBC trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000119312525224053/0001193125-25-224053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000119312525224053/engn-20250930.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-224053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer